Research Article
NAMPT/SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway
Table 1
Clinical characteristics of patients with hypertension and normal undergoing aortic replacement.
| | Normal group () | Hypertension group () | value |
| | Age (years, ) | | | 0.32 | | Male (, %) | 2 (33.3%) | 3 (50%) | 0.599 | | Systolic BP (mmHg, ) | | | 0.002 | | Diastolic BP (mmHg, ) | | | 0.008 | | Mean BP (mmHg, ) | | | 0.006 | | Risk factors | | | | | Smoking (n, %) | 3 (50%) | 2 (33.3%) | 0.599 | | Hypercholesterolemia (, %) | 3 (50%) | 4 (66.7) | 0.609 | | Total cholesterol (mmol/L, ) | | | 0.507 | | BMI (kg/m2, ) | | | 0.493 | | LVEF (%) | | | 0.344 | | Main medication | | | | | Diuretics (, %) | 2 (33.3%) | 3 (50%) | 0.599 | | ACEI/ARB (, %) | 3 (50%) | 4 (66.7) | 0.609 | | β blockers (, %) | 5 (83.3%) | 6 (100%) | 0.341 | | Calcium antagonist (, %) | 2 (33.3%) | 3 (50%) | 0.599 | | Aldosterone antagonist (, %) | 3 (50%) | 4 (66.7) | 0.609 | | HMG CoA inhibitors (, %) | 2 (33.3%) | 4 (66.7%) | 0.29 |
|
|
BP: blood pressure; BMI: body mass index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; HMG-CoA: 3-hydroxy-3-methyl glutaryl coenzyme A.
|
